Inhibition of human tumor cell growth in vivo by an orally bioavailable inhibitor of human farnesyltransferase, BIM-46228

International Journal of Cancer

Volumn 91, Issue 5, 2001, Pages 718-722

  Prevost, Grégoire P ^a,b   Pradines, Anne ^a,b,c   Brezak, Marie Christine ^a   Lonchampt, Marie Odile ^b   Viossat, Isabelle ^a,b   Ader, Isabelle ^a,b   Toulas, Christine ^a   Kasprzyk, Philip ^a   Gordon, Thomas ^a   Favre, Gilles ^a   Morgan, Barry ^b  

^a Institut Henri Beaufour   (France)

^b INSTITUT CLAUDIUS REGAUD   (France)

^c Biomeasure Inc   (United States)

Author keywords

BIM 46228; Bioavailability; Farnesyltransferase; Radio sensitizer; Ras oncogene

Indexed keywords

BIM 46228; PROTEIN FARNESYLTRANSFERASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; COLON CANCER; DRUG BIOAVAILABILITY; DRUG STRUCTURE; ENZYME INHIBITION; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; ONCOGENE RAS; PANCREAS CANCER; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; THYROID CANCER;

3T3 CELLS; ALKYL AND ARYL TRANSFERASES; ANIMALS; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOTTING, WESTERN; CELL DIVISION; COMBINED MODALITY THERAPY; DIMETHYLALLYLTRANSTRANSFERASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; FEMALE; GENES, RAS; HELA CELLS; HUMANS; IMIDAZOLES; INHIBITORY CONCENTRATION 50; LOVASTATIN; MICE; MICE, NUDE; MODELS, CHEMICAL; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; NITRILES; PACLITAXEL; PEPTIDES; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0035283895     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0215(200002)9999:9999<::AID-IJC1104>3.0.CO;2-S     Document Type: Article

References (29)

1. Tumor inhibitory activity of anti-ras ribozymes delivered by retroviral gene transfer
2. Inhibition of anchorage-independent growth of ras-transformed cells on polyHEMA surface by antisense oligodeoxynucleotides directed against K-ras
3. Growth inhibition of human pancreatic cancer cell lines by anti-sense oligonucleotides specific to mutated K-ras genes
4. Inhibitors of prenyl transferases
5. Enzymology and biology of CaaX protein prenylation
6. Farnesyltransferase activity and mRNA expression in human skin basal cell carcinomas
7. Effect of farnesyltransferase overexpression on cell growth and transformation
8. Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice
9. Inhibition of human tumor cell growth in vitro and in vivo by a specific inhibitor of human farnesyltransferase: BIM-46068
10. Antitumor effect of a farnesyl protein transferase inhibitor in mammary and lymphoid tumors overexpressing N-ras in transgenic mice
11. Geranylgeranylated RhoB mediates suppression of human tumor cell growth by farnesyltransferase inhibitors
12. The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis
13. Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to Taxol and epothilones
14. Combination therapy with the farnesyl protein transferase inhibitor SCH66336 and SCH58500 (p53 adenovirus) in preclinical cancer models
15. The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts
16. The farnesyltransferase inhibitor FTI-277 suppresses the 24-kDa FGF2-induced radioresistance in HeLa cells expressing wild-type RAS
17. Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development
18. The CAAX peptidomimetic compound B581 specifically blocks farnesylated, but not geranylgeranylated or myristylated, oncogenic ras signaling and transformation
19. 2 delay and a hyperphosphorylation of p34CDC2 in HeLa cells
20. Inhibitors of anchorage-independent growth affect the growth of transformed cells on poly(2-hydroxyethyl methacrylate)-coated surfaces
21. Evidence for separate mechanisms of antiproliferative action of indomethacin and prostaglandin on MCF-7 breast cancer cells
22. Mean inactivation dose: A useful concept for intercomparison of human cell survival curves
23. Ras CAAX peptidomimetic FTI 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-Ras mutation and p53 deletion
24. K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors
25. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines
26. Farnesyl transferase inhibitors induce apoptosis of Ras-transformed cells denied substratum attachment
27. A peptidomimetic inhibitor of farnesyl: Protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines
28. Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956
29. Prenylation of oncogenic human PTP(CAAX) protein tyrosine phosphatases